GlassScriptPhysician profile
Carmen Daniela Cirstea
NPI 1669442588
$3,622.51
in general payments reported to CMS, 2019-2025
22 companies · $15.91 in 2025
The $15.91 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.35 · 2021: $82.50 · 2022: $761 · 2023: $1,845 · 2024: $900 · 2025: $15.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,130.76 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $432.26 | 2022-2024 | |
| Lilly USA, LLC | $408.30 | 2022-2024 | Emgality, Reyvow |
| Ucb, INC. | $302.12 | 2022-2024 | Briviact, Nayzilam |
| Pfizer INC. | $269.11 | 2023-2024 | |
| Sk Life Science, INC. | $228.13 | 2022-2024 | |
| Genentech USA, INC. | $167.59 | 2023-2024 | Ocrevus |
| Amneal Pharmaceuticals LLC | $155.77 | 2022-2024 | Rytary |
| Boston Scientific Corporation | $119.20 | 2023-2024 | Vercise |
| Lundbeck LLC | $83.02 | 2023-2024 | Rexulti, Vyepti |
| Acadia Pharmaceuticals INC | $81.27 | 2023 | Nuplazid |
| Amgen INC. | $42.00 | 2023 | Aimovig |
| Sunovion Pharmaceuticals INC. | $34.76 | 2022 | |
| Insightec,INC | $29.02 | 2024-2025 | Exablate |
| Corium, LLC | $22.54 | 2023 | Adlarity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $20.99 | 2023 | Dhivy |
| Argenx US, INC. | $20.55 | 2023 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $19.37 | 2023 | Austedo |
| Sumitomo Pharma America, INC. | $19.34 | 2023 | Aptiom |
| Livanova USA, INC. | $18.35 | 2020 | |
| Abbott Laboratories | $18.06 | 2024 | Infinity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Cirstea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.